

Discovery of compounds inhibiting the ADP-ribosyltransferase activity of pertussis toxin

Yashwanth Ashok^{a,#}, Moona Miettinen^{b,c,#}, Danilo Kimio Hirabae de Oliveira^a, Mahlet Z. Tamirat^d, Katja Näreoja^b, Avlokita Tiwari^b, Michael O. Hottiger^e, Mark S. Johnson^d, Lari Lehtiö^{a,*} & Arto T. Pulliainen^{b,*}

^aFaculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Oulu, Finland

^bInstitute of Biomedicine, Research Center for Cancer, Infections, and Immunity, University of Turku, Turku, Finland

^cTurku Doctoral Programme of Molecular Medicine (TuDMM), University of Turku, Turku, Finland

^dStructural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland

^eDepartment of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland

[#] Equal contribution

^{*} Corresponding authors: lari.lehtio@oulu.fi, arto.pulliainen@utu.fi

Corresponding author information:

Dr. Lari Lehtiö, Ph.D.

Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Aapistie
7 B, FI-90220, Oulu, Finland

Phone: +358-2-9448 1169, Fax: not available, E-mail: lari.lehtio@oulu.fi

Arto Pulliainen, Ph.D.

Institute of Biomedicine, Research Center for Cancer, Infections, and Immunity, University of
Turku, Kiinamylynkatu 10, FI-20520, Turku, Finland

Phone: +358-40-1586044, Fax: not available, E-mail: arto.pulliainen@utu.fi

RUNNING TITLE

Inhibitory compounds for pertussis toxin

ABSTRACT

Bordetella pertussis causes the highly contagious respiratory disease pertussis, also known as whooping cough. The resurgence of pertussis has been witnessed even in highly vaccinated populations, and macrolide-resistant strains have been isolated. One attractive target for drug development is the pertussis toxin – an important type IV secretion system-dependent virulence factor of *B. pertussis*. The AB₅-topology pertussis toxin is composed of a pentameric PtxS2-S5 (1:1:2:1) complex mediating toxin binding to cell surface receptors, and one ADP-ribosyltransferase subunit PtxS1. Once internalized into the host cell, PtxS1 ADP-ribosylates α -subunits of heterotrimeric G α i-superfamily members, thereby disrupting G-protein-coupled receptor (GPCR) signaling. Here, we describe protocols to purify mg-levels of truncated but highly active recombinant *B. pertussis* PtxS1 from *E. coli* and an *in vitro* high throughput-compatible assay to quantify NAD⁺ consumption during PtxS1-catalyzed G α i ADP-ribosylation. The *in vitro* NAD⁺ consumption assay was used to screen compounds inhibiting the PtxS1 activity. Two inhibitory compounds (NSC 29193 and NSC 228155) with low micromolar IC₅₀-values were identified that also were potent in an independent *in vitro* assay monitoring conjugation of ADP-ribose to G α i. Docking and molecular dynamics simulations identified plausible binding poses of NSC 228155 and in particular NSC 29193, most likely owing to the rigidity of the latter ligand, at the NAD⁺-binding pocket of PtxS1. NSC 228155 inhibited the pertussis AB₅ holotoxin-catalyzed ADP-ribosylation of G α i in living human cells in low micromolar concentration. NSC 228155 and NSC 29193 might prove useful as lead compounds in targeted drug development in pertussis.

INTRODUCTION

Pertussis, i.e. whooping cough, is a globally distributed acute respiratory disease (1). Pertussis affects all age groups. However, young children are the most affected age group where pertussis may lead to death despite hospital intensive care and use of antibiotics. Worldwide estimates of pertussis cases and deaths in children younger than 5 years in 2014 were 24.1 million and 160,700, respectively (2). Despite efficient global vaccine campaign pertussis remains endemic and recent data, e.g. from USA (3), indicate that the number of pertussis cases is increasing. Sizeable outbreaks have also been reported (1), but the reasons for the resurgence of pertussis are incompletely understood. On the one hand, improved diagnostics and surveillance methods as well as increased awareness of pertussis by health care professionals might contribute (1). On the other hand, molecular changes in the pathogenic *B. pertussis* lineages and waning immunity especially after receipt of acellular pertussis vaccines have been extensively debated (1). These data highlight the need to improve the vaccine formulations and vaccination campaigns, but also to develop alternative means to treat pertussis.

Pertussis toxin is included in the acellular pertussis vaccine formulations in a detoxified form (1), and has provided good protection even as a single component (4). At the same time, clinical isolates lacking pertussis toxin, i.e. vaccine escape mutants, have turned out to be extremely rare (5). Indeed, pertussis toxin is considered as a major virulence factor of *B. pertussis* (6, 7). When administrated systemically to experimental animals, e.g. to mice (8), pertussis toxin recapitulated the leukocytosis (increase in number of circulating white blood cells) seen in young children with pertussis (1). Rats experimentally infected with *B. pertussis* developed paroxysmal coughing lasting several days, but an isogenic pertussis toxin-deficient strain did not cause such pathology (9, 10). Seven-day-old neonatal mice infected with a pertussis toxin-deficient strain of *B. pertussis* fully survived a challenge, which caused 100% mortality with the parental strain (11).

Therefore, targeting of pertussis toxin might prove beneficial in the treatment of pertussis, especially in young children who still lack the vaccine-induced protection against pertussis.

Pertussis toxin is composed of five non-covalently bound subunits (PtxS1-S5), which are arranged in an AB₅-topology (12, 13). The B₅-assembly is formed by the PtxS2-S5 subunits (PtxS2, PtxS3, 2 copies of PtxS4, PtxS5) (12, 13). Pertussis toxin is secreted from the bacteria via Sec-pathway and Ptl type IV secretion system (14). The B₅-assembly mediates binding of the secreted AB₅ holotoxin on the surface of various different cell types in a carbohydrate-dependent manner (13). Subsequent cell entry is followed by dissociation of the B₅-assembly and the PtxS1-subunit (15), which belongs to the family of ADP-ribosyltransferases (16). PtxS1 ADP-ribosylates a single C-terminal cysteine residue in α -subunits of most heterotrimeric G α i-superfamily members such as G α i, G α o, and G α t (17-19). The C-terminus of the heterotrimeric G-protein α -subunits makes functionally important contacts with the plasma membrane-localized G-protein coupled receptors (GPCRs) (20). Therefore, the bulky PtxS1-catalyzed ADP-ribose modification decouples the G-protein α i-subunit from the GPCRs and inhibits signal propagation initiated upon agonist stimulation of GPCRs.

Seven-day-old neonatal mice infected with a *B. pertussis* strain expressing a catalytically inactive mutant of PtxS1 fully survived a challenge, which causes 100% mortality with the parental strain of *B. pertussis* (11). Purified AB₅ holotoxin containing the same PtxS1 mutant is incapable of inducing leukocytosis in mice in doses that are 100-fold more than the median lethal dose of wild-type AB₅ holotoxin (21). It appears, therefore, that the enzymatic activity of PtxS1 is important for the pathological effects of pertussis toxin. In this study, we set out to identify small molecular weight compounds inhibiting the G α i-specific ADP-ribosyltransferase activity of pertussis toxin, and thereby to interfere with the cellular effects of pertussis toxin.

RESULTS

Purification of recombinant PtxS1 from *E. coli* – We did not succeed in purifying the full length N- or C-terminally HIS-tagged recombinant PtxS1 from *E. coli* due to weak solubility and proteolytic instability (data not shown). Therefore, we engineered a double deletion to *ptxA* resulting into expression of an N-terminally HIS-tagged version of *B. pertussis* Tohama I strain PtxS1 (UniProt_P04977), referred hereafter to as rPtxS1, which lacks the N-terminal secretion signal sequence as well as part of the C-terminus (Fig. 1, Fig. 2A). The C-terminal truncation exposes the ADP-ribosyltransferase (ART) catalytic site of PtxS1 including the NAD⁺-binding pocket (Fig. 1)(12, 13). Structural data of the pertussis AB₅ holotoxin demonstrate that the C-terminus of PtxS1 masks the active site, and indicate that di-sulfide bond reduction and significant movement of the C-terminus would be required for catalysis (12, 13).

rPtxS1, as purified with metal affinity and size exclusion chromatography, is proteolytically stable and migrates between the 25 and 20 kDa protein markers in SDS-PAGE (Fig. 2B), in accordance with a theoretical size of 23.4 kDa. In order to study the oligomerization state of rPtxS1 in solution, size exclusion chromatography coupled to static light scattering (SEC-MALS) was used. Purified rPtxS1 appeared as a single peak (Fig. 2C), with an estimate of 23.04 ± 0.2 kDa in a triplicate run indicating that rPtxS1 is monomeric in solution. rPtxS1 is well folded as evidenced by a sigmoidal curve with a melting temperature (T_m) of 51°C in a differential scanning fluorimetry (DSF)-assay (Fig. 2D).

Analysis of the ART activity of rPtxS1 – ART activity of rPtxS1 towards Gαi was first studied with a HEK293T cell membrane preparation having an endogenous level of Gαi in an NAD⁺-biotin Western blot-assay. rPtxS1 ADP-ribosylated one major protein from the complex

membrane proteome (Fig. 2E). This protein migrated between the 55 and 35 kDa protein markers in SDS-PAGE (Fig. 2E), in accordance with a theoretical size of endogenous Gai, e.g. 40.4 kDa for isoform 1 (UniProt_P63096). Next, ART activity of rPtxS1 towards Gai was studied with recombinant N-terminally HIS-tagged Gai (isoform 1, UniProt_P63096) purified from *E. coli*, hereafter referred to as rGai, in an NAD⁺ Western blot-assay. rPtxS1 ADP-ribosylated rGai (Fig. 2F), indicating that Gai may efficiently serve as a substrate without the G-protein $\beta\gamma$ -complex or other cellular constituents. SEC-analysis of rPtxS1-rGai complex solution topology shows the presence of only single monomeric rPtxS1 and rGai proteins (Fig. S1). rPtxS1-rGai complex formation during catalysis therefore appears to be weak, i.e. the rGai modification is based on a transient kiss-and-run interaction. Interestingly, rPtxS1 modifies itself (Fig. 2E), and it already had become auto-ADP-ribosylated in the *E. coli* expression host (Fig. 2F). This activity was drastically diminished in a Q127D/E129D double mutant of rPtxS1, hereafter referred to as rPtxS1-mutant (Fig. S2A). The rPtxS1-mutant was also incapable of ADP-ribosylating rGai (Fig. S2B). This double mutant of rPtxS1 was analyzed, because structurally identical mutations in a recently discovered pertussis-like toxin from *E. coli* caused catalytic inactivation, although NAD⁺ was still capable of binding to the protein (22)(Fig. S2C). Q127 and E129 of rPtxS1 are also conserved with several other bacterial ART-toxins where these residues position NAD⁺, in particular the nicotinamide end (Fig. S2C), and promote the transfer of ADP-ribose to a substrate amino acid residue (16). To assess the substrate amino acid specificity of the extensively truncated rPtxS1 (see Fig. 1 and Fig. 2A), we analyzed the C351A mutant of rGai (UniProt_P63096), hereafter referred to as rGai-mutant, in an NAD⁺-biotin Western blot-assay. rPtxS1 ADP-ribosylated rGai, but it was incapable of ADP-ribosylating the rGai-mutant (Fig. S3). Based on a DSF-assay, the T_m of the rGai-mutant was 44.33 ± 0.23 °C as compared to T_m

of the rGai-wt (T_m of 43.83 ± 0.23 °C), indicating that the C351A mutation does not affect the protein folding. Therefore, rPtxS1 is not only catalytically active towards rGai, but it also retains the Gai substrate amino acid specificity evidenced with the pertussis AB₅ holotoxin (17-19).

Multiwell-based assay set-up for screening of rPtxS1 inhibitors – We analyzed the suitability of a fluorometric method to screen for rPtxS1 inhibitors previously developed for poly-ADP-ribose synthesizing enzymes (23) and later extended to mono-ADP-ribose synthesizing enzymes (24). Briefly, the end point assay is based on conversion of NAD⁺ to a stable fluorophore with emission maximum at 444 nm (23). The decrease in fluorescence in comparison to the non-enzyme control is a measure of NAD⁺-consuming enzymatic activity (23). Incubation of rPtxS1 with rGai for 40 min resulted in a strong decrease of fluorescence, almost comparable to the fluorescence signal obtained with the buffer control where no NAD⁺ was added to the reaction (Fig. 3A). No fluorescence decrease was detected with the rPtxS1-mutant under identical conditions (Fig. 3A). Assays with different concentrations of rPtxS1 were stopped at various time points to measure NAD⁺ consumption in the presence of a constant amount of rGai substrate. These data demonstrate that an increase in the rPtxS1 concentration increases NAD⁺ consumption that also progresses over time (Fig. 3B). These results indicate that the detected reduction in fluorescence is not an effect of fluorescence quenching but indeed NAD⁺-consuming activity of rPtxS1. rPtxS1 could also consume NAD⁺ in the absence of rGai, although much slower than with the rGai substrate (Fig. 3A). This NAD⁺ glycohydrolase activity, i.e. enzyme-catalyzed reaction between NAD⁺ and water to yield ADP-ribose and nicotinamide, was not detected with the rPtxS1-mutant (Fig. 3A). The effect of DMSO on the NAD⁺-consuming activity of rPtxS1 was also studied because small molecules in chemical libraries are usually dissolved in

DMSO typically resulting in assay concentrations of 0.1% – 1% DMSO. DMSO did not have a significant effect on the NAD⁺-consuming activity of rPtxS1 in the presence of rGai substrate up to 0.2% DMSO, while 1% DMSO already significantly ($p = 10^{-4}$) reduced activity (Fig. 3C). We chose to perform screenings in the presence of 0.1% DMSO. To test reproducibility of the fluorometric assay, maximum (NAD⁺ as incubated in plain buffer) and minimum (NAD⁺ as incubated in rPtxS1- and rGai-containing buffer) signals were measured from five independent runs to test plate-to-plate and day-to-day variability. The average Z' value for the assay was 0.68, indicating that the fluorometric assay is suitable for high throughput screening. The statistical parameters of the assay are summarized in Table S1.

Screening for rPtxS1 inhibitors – We screened a chemical library of 1,695 compounds obtained from the National Cancer Institute (NCI) Developmental Therapeutics program repository (<https://dtp.cancer.gov/>). A total of nine compound hits were identified, which inhibited the NAD⁺-consumption activity of rPtxS1 in the presence of rGai more than 50% (screening data not shown). These nine compounds were analyzed in an independent NAD⁺-biotin Western blot-assay, which measures the ADP-ribosylation activity of rPtxS1, i.e. rPtxS1-catalyzed conjugation of ADP-ribose-biotin onto rGai. Five out of the nine primary compound hits showed strong inhibition of the rPtxS1 ADP-ribosylation activity (Fig. 4A). NSC 119875 (Cisplatin, DNA alkylating agent used in cancer treatments) and NSC 44750 affected rGai and/or rPtxS1 protein integrity in the NAD⁺-biotin Western-blot based assay (Fig. 4A), even if the assay was performed with a 10-fold lower compound concentration (data not shown). NSC 119875 and NSC 44750 were therefore excluded from further studies. To evaluate the potency of the remaining three compounds for rPtxS1 inhibition, dose response studies were performed using the fluorometric NAD⁺-consumption assay in the presence of rGai. Two of the compounds had an IC₅₀-value of <

10 μ M with NSC 228155 and NSC 29193 having an IC_{50} -value of 3.0 and 6.8 μ M, respectively (Fig. 4B). NSC 149286 was less potent than the other two compounds with an IC_{50} -value of 20 μ M (Fig. 4B), and was excluded from further analyses. We did not detect NSC 228155- or NSC 29193-induced transition of the rPtxS1 sigmoidal melting curves towards higher temperatures in a DSF-assay (Fig. S4). This indicates that either the compound binding is not sufficient to alter the thermal stability of rPtxS1 fold, or that the compound affinity to rPtxS1 is low. Importantly, the transition of the sigmoidal melting curve towards lower temperatures was also not evident, indicating that the compounds do not destabilize rPtxS1. The two hit compounds were not identified as pan-assay interference compounds or aggregators (zinc15.docking.org). In summary, compound library screening resulted into identification of two compounds (NSC 228155 and NSC 29193), which inhibited the rPtxS1-catalyzed ADP-ribosylation of rG α i.

Putative binding poses of NSC 29193 and NSC 228155 to PtxS1 – In order to evaluate possible binding modes of the compounds to PtxS1, we performed docking and molecular dynamic simulations (MDS). Docking of NSC 228155 produced multiple binding poses but some features were shared among the top ranked poses, including the placement of the aromatic pyridine ring of NSC 228155 in an enclosed region where the nicotinamide ring of NAD⁺ would bind to PtxS1, with the double benzoxadiazole ring positioned near the center of the NAD⁺-binding pocket. The benzoxadiazole ring is joined to the pyridine ring via a central sulfur atom, and the rotatable bonds permit the adoption of varying conformations. In pose 1 (Fig. 5A), with the lowest free energy of binding (ΔG_{bind} of -51.2 kcal/mol; docking score of -4.08 kcal/mol), the pyridine ring oxygen of the ligand forms a hydrogen bond with the main-chain nitrogen atom of Tyr10, anchoring the ligand to an aromatic area of the binding pocket, and with π - π stacking interactions observed for the pyridine ring with nearby Tyr59 and for the benzoxadiazole ring

with Tyr63. In pose 2 (Fig. 5B), having the best docking score (-4.20 kcal/mol; ΔG_{bind} of -43.3 kcal/mol), the pyridine ring is rotated 90° relative to pose 1, losing the backbone hydrogen bond with Tyr10, but making π - π interactions with both Tyr63 and Tyr10, and ionic interactions with Arg9 and Arg67. In MDS, pose 1 showed stability and retains its position with respect to the original docked position, only differing on average by an RMSD of 0.9 Å (Fig. S5A), and the RMSD for the ligand orientations differ on average by 2.3 Å when the coordinates of PtxS1 are superposed over the backbone atoms. In contrast, pose 2 was very unstable at the initial binding position and occupied different locations of the binding pocket with an average 22 Å RMSD for the ligand based on superposing the PtxS1 coordinates from the simulation (Fig. S5B).

In contrast to NSC 228155, NSC 29193 is rigid and almost exclusively resulted in two docked poses. Pose 1 of NSC 29193 is positioned near the binding site for the nicotinamide ring of NAD⁺ in the PtxS1, hydrogen bonding with main-chain nitrogen and oxygen atoms of Tyr10 (Fig. 5C). Additionally, NSC 29193 forms π -cation interactions with Arg9, π - π stacking with Tyr63 and hydrogen bonding with the side-chain hydroxyl group of Ser52. NSC 29193, pose 2, is bound near the location where the adenine ring of NAD⁺ would be bound in the pertussis toxin, stacking against the aromatic ring of Trp26 and hydrogen bonding with the main-chain oxygen atom of Thr24 (Fig. 5D) as well as forming ionic interactions with Arg9 and Arg13. During MDS, NSC 29193 pose 1 was quite stable, with an average RMSD of 0.1 and 1.0 Å with respect to the ligand and receptor backbone atoms (Fig. S5C), and interactions between the ligand and main-chain atoms of Tyr10 were conserved for over 90% of the simulation time. The π - π interactions with Tyr63 and π -cation interactions with Arg9 were also retained for the majority of the simulation time. In contrast, the binding mode of pose 2 was disrupted at around 20 ns of the simulation (Fig. S5D), mainly due to the reorientation of the indole ring of Trp26, which appears to be one of the key interaction partners of NSC 29193. Consequently, in pose 2 the ligand moves

from the initial binding position and binds to several areas of the binding pocket. This is reflected by the average 12 Å RMSD of the ligand with respect to the superposed coordinates of the toxin from the simulation (Fig. S5D). Taken together, docking and MDS resulted in identification of plausible binding poses of NSC 228155 and in particular for NSC 29193, most likely owing to the rigidity of the latter ligand, at the NAD⁺-binding pocket of PtxS1.

Inhibitory action of NSC 228155 and NSC 29193 in a living human cell-based assay – First, to find the optimal toxin dosage, we titrated the pertussis AB₅ holotoxin and detected the ADP-ribosylation of endogenous Gai by Western blot-assay using a polyclonal mono-ADP-ribose-recognizing antibody. Incubation of cells for 2 h with the holotoxin resulted, in a concentration dependent-manner, mono-ADP-ribosylation of a single protein migrating between the 35 and 55 kDa protein markers in SDS-PAGE (Fig. 6A), in accordance with a theoretical size of endogenous Gai, e.g. 40.4 kDa for isoform 1 (UniProt_P63096). Next, we pre-incubated the cells with the compounds NSC 228155 or NSC 29193 prior to addition of the holotoxin and subsequent co-incubation. We did not detect any inhibitory action for the compound NSC 29193 despite multiple analyzed conditions (data not shown), e.g. i) 30 min pre-incubation with inhibitor (0.1, 1, 10 and 50 µM) + 2 h with holotoxin (10 ng/mL) or ii) 1, 2, 3, 4 and 5 h pre-incubation with 50 µM inhibitor + 2 h with holotoxin (10 ng/mL). However, compound NSC 228155 inhibited the Gai-specific ADP-ribosylation activity of holotoxin in a concentration-dependent manner (Fig. 6B). Pre-incubation of the cells for 30 min with 5 µM of NSC 228155 prior to holotoxin addition and subsequent co-incubation resulted in a near complete inhibition of mono-ADP-ribosylation of Gai (Fig. 6B). Importantly, NSC 228155 inhibited the holotoxin activity in concentrations that were not deleterious for the cell viability. First of all, we did not detect major visual alterations in HEK293T monolayers upon 5 µM NSC 228155 incubation

during the 2.5 h *in vivo* ADP-ribosylation assay period (data not shown). Secondly, cell viability, as analyzed by the MTT-assay at 3.5 h after addition of NSC 21855, was significantly affected only after 20 μ M or higher concentration was used (Fig. S6A). IC₅₀ of the NSC 228155 cytotoxicity in HEK293T was 15.33 μ M (Fig. S6A). Thirdly, 5 μ M NSC 228155 did not significantly increase the DNA-damage induced PARP1 (also called ARTD1) poly-ADP-ribosylation or cell death-associated PARP1/ARTD1 proteolytic processing from the approximately 120 kDa full length form into approximately 90 kDa form (Fig. S6B). Taken together, compound NSC 228155 inhibits the AB₅ holotoxin-catalyzed ADP-ribosylation of G α i in living HEK293T cells in concentrations that are not deleterious for the cell viability.

DISCUSSION

We report the identification of the first small molecular weight compounds inhibiting the ADP-ribosyltransferase activity of pertussis toxin *in vitro* and in living cells. Compound library screening was made possible due to our ability to purify mg-levels of a truncated but highly active recombinant PtxS1 (rPtxS1) under native conditions from *E. coli*. Moreover, rPtxS1 retained the high amino acid specificity of pertussis AB₅ holotoxin toward the single C-terminal cysteine in G α i (17-19). Used truncation positions in rPtxS1 are functionally justified. PtxS1 contains an N-terminal signal sequence ending at Ala34 (25, 26) that gets cleaved upon the Sec-mediated secretion of PtxS1 from the cytoplasm into the periplasm where the AB₅ holotoxin is assembled prior to Ptl type IV secretion system-mediated export. Asp35 is classically numbered as the first amino acid of mature PtxS1 (see Fig. 2). The truncated part of the PtxS1 C-terminus (see Fig. 1, 2A) masks the NAD⁺-binding pocket in the AB₅ holotoxin involving a stabilizing intramolecular di-sulfide bond between Cys41 and Cys201 (12, 13). Our truncation approach bypasses the need for disulfide bond reduction (27) and extensive conformational movement of

the C-terminus (12, 13) to activate PtxS1, which inside the host cell has also been proposed to involve proteolysis (28).

The inhibitory compounds NSC 29193 and NSC 228155 with low micromolar IC₅₀-values were identified in the *in vitro* NAD⁺ consumption assay from a chemical library of 1,695 compounds. These compounds were also potent in an independent *in vitro* assay where we monitored the amount of rGai-conjugated ADP-ribose-biotin upon rPtxS1 catalysis by streptavidin-HRP Western blotting (see Fig. 4A). It is noteworthy that other compounds were also positive in the *in vitro* NAD⁺ consumption assay, but apparently via deleterious effects for protein stability as evidenced by the independent *in vitro* ADP-ribose conjugation assay, i.e. compounds NSC 44750 and NSC 119875 (cisplatin) (see Fig. 4A). We did not detect NSC 228155- or NSC 29193-induced transition of the rPtxS1 sigmoidal melting curves towards higher temperatures in a DSF-assay (see Fig. S4). This indicates that either the compound binding is not sufficient to alter the thermal stability of rPtxS1 fold, or the affinity of the compounds to rPtxS1 is low. With respect to NSC 228155, we also attempted to utilize its inherent fluorescence (29) in a fluorescence polarization assay, but we did not detect significant changes in fluorescence polarization to make reliable conclusions on the affinity of NSC 228155-rPtxS1 interaction (data not shown). Our docking and molecular dynamic simulations resulted in variability among poses for both ligands. More consistent, energetically favorable binding poses were observed for NSC 29193. This is in accordance with the compound structures (see Fig. 4C). NSC 29193 (purine-2,8-dithiol) is a rather rigid purine analogue that mimics the structure of the adenine base of NAD⁺. NSC 228155, on the other hand, contains two major molecular structures, connected by a rotatable linker, one ring compound mimicking the adenine base of NAD⁺ and the other ring compound mimicking the nicotinamide of NAD⁺. In summary, compound library screening

resulted into the identification of two compounds, NSC 29193 and NSC 228155, which inhibited the rPtxS1-catalyzed ADP-ribosylation of rGai *in vitro*.

NSC 228155, but not NSC 29193, was a potent inhibitor of pertussis holotoxin-mediated ADP-ribosylation of Gai in living HEK293T cells. We tried multiple different experimental set-ups with NSC 29193 (see Results section, last chapter), including concentrations as high as 50 μ M that still did not cause visible alterations for HEK293T cell monolayers. In respect of previous drug screening approaches there appears to be little if any published information on NSC 29193. The cell permeability of NSC 29193 is not known, but might be weak and thus explain our negative inhibitory data. In sharp contrast, we detected a near complete inhibition of the ADP-ribosylation with 5 μ M NSC 228155 (see Fig. 6). In part, this could relate to the fact that NSC 228155 easily permeates cells. It has been shown in MDA-MB-468 breast cancer cells that 5 min incubation with 100 μ M NSC 228155 caused rapid movement of this inherently fluorescent molecule across cell membranes and dispersal to both the cytoplasm and nucleus (29). However, we witnessed significant toxicity of NSC 228155 for HEK293T cells with 20 μ M or higher concentrations after a 3.5-h incubation (cytotoxicity IC_{50} – 15.33 μ M). This cytotoxicity might be caused by the proposed NSC 228155-mediated production of reactive oxygen species (ROS) inside the cell (29). In this respect, it is noteworthy that, upon incubation of cells with 5 μ M of NSC 228155 for 2.5 h, we did not detect auto-ADP-ribosylation of PARP1/ARTD1 (see Fig. S6), which is induced in cells upon ROS-induced DNA damage (30). Moreover, we did not detect caspase-mediated proteolytic PARP1/ARTD1 cleavage (see Fig. S6), which is a robust readout for the onset of programmed cell death. However, future lead development needs to address the apparent cell toxicity effects of NCS 228155. Taken together, NSC 228155 is a cell permeable and potent compound to inhibit pertussis holotoxin-mediated ADP-ribosylation of Gai in living cells in low micromolar concentration.

Resurgence of pertussis has been witnessed even in highly vaccinated populations (1-3), and there are no specific therapeutics to treat whooping cough. Macrolide antibiotics, when administrated at a very early stage, show therapeutic effects in certain patient subgroups such as in infants <3 months of age (31). However, macrolide resistant *B. pertussis* strains have been reported (32, 33). Pertussis toxin is a major virulence factor of *B. pertussis*, and appears to contribute to the development of whooping cough (6-11). Targeting of pertussis toxin might prove beneficial in the treatment of whooping cough, especially in young children who still lack the vaccine-induced protection against pertussis. In this respect, several drug modes of action could be envisioned, including to inhibit – i) secretion, ii) host cell recognition, iii) endocytosis, iv) intracellular trafficking, and v) enzymatic activity (i.e. ADP-ribosylation) inside the host cell. Humanized monoclonal antibodies have been developed that block pertussis toxin cell surface receptor interaction or the subsequent internalization and retrograde trafficking (34). These humanized antibodies prevented the characteristic signs of pertussis in mouse and baboon models (35). Our current study shows that small molecular weight compounds inhibiting the ADP-ribosyltransferase activity of pertussis toxin might also have therapeutic potential. Similar findings have been published on other ADP-ribosylating bacterial toxins, such as ExoA and ExoS of *Pseudomonas aeruginosa* and cholix-toxin of *Vibrio cholerae* (36, 37). We conclude that NSC 29193 and NSC 228155 are useful templates for future lead development to specifically inhibit pertussis toxin activity, the immediate challenge being to enhance target specificity and to increase affinity.

MATERIALS AND METHODS

Expression plasmids – i) *rPtxS1-wt* Synthetic DNA fragment (Eurofins Genomics) encoding for amino acids D35-I221 of *Bordetella pertussis* strain Tohama I (UniProt_P04977) was cloned with NdeI and BamHI into pET15b (Novagen) allowing expression of an N-terminally HIS-tagged rPtxS1 (MGSSHHHHHSSGLVPRGSHM-D35-PtxS1-I221). The D35-I221 truncation positions of PtxS1 are based on (38). Of note, Asp35 is classically numbered as the first amino acid of PtxS1. **ii) *rPtxS1-Q161D/E163D*** pET15b-rPtxS1 plasmid was linearized with PCR using 5'-phosphorylated oligonucleotide primers (Eurofins Genomics) prAPV-351 (GATAGCGATTATCTGGCACACCGGCGCATTCCG, mutagenic nucleotides underlined) and prAPV-352 (GTAGGTGGCCAGCGCGCCGGCGAGGATACG). The PCR product was gel-isolated, re-ligated and transformed to acquire the mutant plasmid. **iii) *rGai-wt*** Synthetic DNA fragment (GenScript) encoding for *E. coli* codon-optimized full-length human Gai (isoform 1, UniProt_P63096-1) was cloned into pNIC-Bsa4 (Structural Genomics Consortium) using the ligation independent cloning method allowing expression of an N-terminally HIS-tagged rGai (MHHHHHHSSGVLDLTENLYFQS-Gai). **iii) *rGai-Cys351Ala*** rGai-encoding plasmid was used as a template in PCR to amplify Cys351Ala-mutant-encoding mutant allele using oligonucleotide primers (Eurofins Genomics) prAPV-418 (tactccaatccATGGGTTGCACCCTGAGCGCGGAA, LIC-cloning overhangs in lowercase) and prAPV-419 (tatccacctttactgTCAGAACAGGCCCGCATCCTTCAGGTTGTTCTTG, mutagenic nucleotides underlined, LIC-cloning overhangs in lowercase). The PCR product was cloned into pNIC-Bsa4 (Structural Genomics Consortium) using the ligation independent cloning method allowing expression of an N-terminally HIS-tagged rGai-Cys351Ala mutant similar to rGai-wt. All expression plasmids were verified by sequencing.

Protein expression and purification – Expression plasmids were transformed into BL21(DE3) (Novagen) and selected overnight at 37°C on Luria-Bertani (LB) agar with appropriate antibiotics. Next morning, the bacterial lawn from the LB-plates was transferred into Terrific broth autoinduction medium (Formedium, AIMTB0205) supplemented with 0.8% (w/v) of glycerol with appropriate antibiotics. Cultures were grown at 37°C with 250 rpm until optical density at 600 nm reached 1 (typically 3-5 h), and temperature was reduced to 18°C. Bacteria were collected after 24 h by centrifugation and were either frozen to -80°C as pellets, in lysis buffer or directly used for purification. Pefabloc protease inhibitor (Roche, 11585916001) was added to 0.1 mM in the thawed biomass in lysis buffer [100 mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) glycerol, 0.5 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 10 mM imidazole]. Samples were sonicated and clarified by centrifugation. Supernatant was loaded to 5 mL HisTrap HP column (GE Healthcare). With rPtxS1 proteins, column was washed with 10 column volumes of wash buffer I and II. Wash buffer I and II have identical compositions to lysis buffer with the exception of imidazole concentration of 25 and 50 mM, respectively. rPtxS1 proteins were eluted with elution buffer [100mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP, 500 mM imidazole], concentrated using a 10 kDa cut-off concentrator (Thermo Scientific) and subjected to size exclusion chromatography on Superdex75 16/600 Hiload Superdex column (GE Healthcare) using SEC buffer [100 mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP]. With Gai proteins, HisTrap HP column was washed with 15 column volumes of wash buffer [20mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP, 25 mM imidazole] and eluted with elution buffer [20 mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP, 500 mM imidazole]. Fractions were concentrated using a 10 kDa cut-off concentrator (Thermo Scientific) and further purified by size

exclusion chromatography on Superdex75 16/600 Hiload Superdex column (GE Healthcare) with SEC buffer [30 mM Hepes (pH 7.5), 350 mM NaCl, 1 mM MgCl₂, 0.5 mM TCEP]. Protein fractions were pooled, concentrated using a 10 kDa cut-off concentrator (Thermo Scientific), flash frozen and stored in -80°C.

Static light scattering – All experiments were conducted with SEC-MALS buffer [100 mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP] with a flow rate of 0.150 mL per minute. Buffer was filtered with 0.1 µm filter to remove small particles. Typically 100 µg of protein samples were injected into Superdex 200 10/300 increase column (GE Healthcare) by a Shimadzu autosampler coupled HPLC machine. Light scattering data were recorded using a multiangle light scattering detector (miniDAWN TREOS, Wyatt technology). Data were analyzed using Astra software (Wyatt technology). For complex formation studies, 1:1 molar ratio of rPtxS1 and rGαi (100 µg in total) was incubated on ice for 2 h and then injected into the column.

Differential scanning fluorimetry (DSF) – rPtxS1 at a concentration of 0.25 mg/mL was used in PBS. Protein was incubated with 5 × SYPRO orange (Thermo Scientific) for 10 minutes. The samples were heated from 20-90°C with 1°C increments (1 min/1°C). The experiment was run on 2500 Real-Time PCR systems (Applied Biosystems). The resulting data was analyzed with Boltzmann sigmoidal equation using GraphPad (GraphPad software, Inc.). Thermal stability of rGαi, rGαi-mutant and rPtxS1 alone as well as in the presence of NSC 228155 or NSC 29193, was analyzed by DSF using a CFX96 Real-Time PCR detection system (Bio-Rad). rGαi, rGαi-mutant and rPtxS1 at a concentration of 0.2 mg/mL was used in 20 mM Hepes (pH 7.5), 500 mM

NaCl, 10% (w/v) glycerol, 0.5 mM TCEP. The inhibitor concentrations used in the assay ranged from 50 μ M to 1 mM. Samples were incubated with 5 \times SYPRO Orange (Thermo Scientific) for 5 min. The samples were heated from 20-90°C with 0.5°C increments (1 min/1°C). T_m-values were determined by using the CFX96 Real-Time PCR detection system (Bio-Rad) software.

***In vitro* ADP-ribosylation assays – i) enzyme-excess condition** Reactions (typically in 120 μ L) contained 10 μ M rPtxS1 proteins, 10 μ M biotinylated NAD⁺ (Trevigen, 4670-500-01) or 10 μ M NAD⁺ (Sigma, N3014) and either 4 μ M rGai proteins or membrane fraction of HEK293T cells (30 μ g of total protein) as the substrate in 100 mM Hepes (pH 7.5), 500 mM NaCl and 10% (w/v) glycerol. The membrane fraction was prepared essentially as described in (39). 80% confluent 10 cm cell culture plate of HEK293T cells was placed on ice and washed twice with PBS. Cells were collected by scraping into 1 mL of hypotonic lysis buffer [20 mM Hepes (pH 7.5), 2.5 mM MgCl₂, 1 mM DTT supplemented with Pierce Protease and Phosphatase Inhibitor Mini Tablets (40 μ L/mL of stock solution – one tablet / 2 mL H₂O, Thermo Scientific, 88668) and 25 U/mL of benzonase (Merck-Millipore, 70664-3)]. The cells were incubated at 4°C for 1 h in rotation to allow them to swell and partially lyse. The partial lysates were drawn 20 times through 27-gauge needles and centrifuged with low speed (600 \times g, 4°C, 10 min) to pellet the nuclei and insoluble cell debris. The low-speed supernatant was subjected to high-speed centrifugation (16100 \times g, 4°C, 30 min) to pellet the membranes. The membranes were resolubilized into 50 μ L of 50 mM Hepes (pH 7.5), 200 mM NaCl, 1 mM EDTA and 10 mM DTT, 0.3% (w/v) SDS and 2% Triton X-100 supplemented with protease and phosphatase inhibitors, in concentration as described above. Protein concentration was measured with Bradford assay. The ADP-ribosylation reactions were carried out at room temperature for 3 h with shaking at 300 rpm. Reactions were stopped by

473 addition of Laemmli loading dye to 1 × and heating for 10 minutes at 95°C. The samples were
 474 run on SDS-PAGE and transferred to nitrocellulose membranes, followed by blocking with 1%
 475 (w/v) casein blocking buffer (Bio-Rad, 161-0782). Membranes were incubated with streptavidin
 476 conjugated to horse radish peroxidase (1:5000) (GE Healthcare, RPN1231VS) in 1% (w/v) casein
 477 blocking buffer (Bio-Rad, 161-0782) for 3 h at 4°C in rotation and washed thrice with Tris-
 478 buffered saline [10 mM Tris-HCl (pH 7.5), 150 mM NaCl] containing 0.05% Tween 20 (TBST)
 479 for ten minutes each time. Alternatively, after blocking with 4% (w/v) BSA in TBST, membranes
 480 were probed in TBST containing 2% (w/v) BSA (24 - 48 h at 4°C in rotation) for HIS-tagged
 481 rPtxS1 and rGai proteins with mouse monoclonal anti-HIS (1:1000) (R&D Systems, MAB050),
 482 for Gai with mouse monoclonal anti-Gai (1:500) (Santa Cruz Biotechnology, sc-136478) or
 483 mono-ADP-ribose with a rabbit polyclonal anti-mono-ADP-ribose (1:1000) antibody (Hottiger-
 484 laboratory). Primary antibody membranes were washed thrice with TBST containing 2% (w/v)
 485 BSA for ten minutes each time. Primary antibody membranes were incubated with mouse IgG
 486 kappa binding protein conjugated to horseradish peroxidase (1:2500) (sc-516102, Santa Cruz
 487 Biotechnology) or goat anti-rabbit IgG conjugated to horseradish peroxidase (1:2500) (sc-2004,
 488 Santa Cruz Biotechnology) for 3 h at 4°C in rotation and washed thrice with TBST for ten
 489 minutes each time. All membranes were subsequently developed with WesternBright ECL
 490 (Advansta) and imaged on ImageQuant LAS 4000 (GE Healthcare). **ii) substrate-excess**
 491 **condition** Reactions (typically in 50 µL) contained 50 nM PtxS1 proteins and 500 nM Gai in 50
 492 mM sodium phosphate (pH 7.0) and 1 µM biotinylated NAD⁺ (Trevigen, 4670-500-01). The
 493 reactions were carried at room temperature for 40 minutes. For validating hits from chemical
 494 screening, 10 µM of the indicated compound and 0.1% DMSO (control reaction) were used.
 495 Reactions were stopped by addition of Laemmli loading dye to 1 × and heating for 3 minutes at

90°C. The samples were run on SDS-PAGE and transferred to nitrocellulose membranes, followed by blocking with 1% (w/v) casein blocking buffer (Bio-Rad, 161-0782). Membranes were incubated with streptavidin conjugated to horse radish peroxidase (1:7000) (PerkinElmer, NEL750001EA) in 1% (w/v) casein blocking buffer (Bio-Rad, 161-0782) for 3 h at 4°C in rotation and washed thrice with TBST for ten minutes each time. Alternatively, for anti-His blotting, Penta His HRP conjugate (Qiagen, 34460) was diluted 1:5000 in 1% (w/v) casein blocking buffer (Bio-Rad, 161-0782). Blots were incubated at room temperature for 2 h, followed by 3 washes with TBST each for 5 minutes. Membranes were subsequently developed with WesternBright ECL (Advansta) and imaged on ChemiDoc XRS+ (Bio-Rad).

***In vitro* NAD⁺ consumption assay – i) basic reaction set-up** Reactions were carried out in a U-shaped 96-well black plate (Greiner BioOne, 650209). Typically, reactions were conducted with 50 mM sodium phosphate (pH 7.0) at 25°C with shaking at 300 rpm with a reaction volume of 50 µL. The reactions were stopped by adding 20 µL of 20% acetophenone (diluted with ethanol) and 20 µL of 2M KOH and incubated at room temperature for 10 minutes. 90 µL of formic acid was added and further incubated for 20 minutes. The plates were read using Tecan infinity M1000 pro with excitation and emission wavelengths set at 372 and 444 nm, respectively. Maximum signal was defined as the NAD⁺ buffer control and the minimum signal was the rPtxS1-catalyzed reaction in the presence of rGai. The raw fluorescence values were always subtracted from blank containing buffer. The assay was optimized to reach 60% NAD⁺ consumption. The optimized conditions for the assay are 125 nM rPtxS1, 500 nM NAD⁺ and 1 µM rGai. The reaction has incubation time of 40 minutes at 25°C with shaking at 300 rpm. The DMSO concentration used was 0.1%. DMSO tolerance test was done with optimized conditions (0.1-5%). For rGai substrate-independent NAD⁺ consumption activity of rPtxS1, identical conditions were used

except that rGai was excluded with longer incubation time of 60 minutes. Statistical analyses on typically 8 parallel values was conducted using two-tailed Student's t-test two sample equal variance (homoscedastic). **ii) validation of the NAD⁺ consumption assay** In order to establish repeatability of values for maximum and minimum signals between plates, wells and days, five control plates were tested. Experimental conditions and protein batches used for assay validation were the same. Three plates were made on one day while second and third days had one plate each. Each plate had 40 wells for maximum and minimum signals individually with buffer blanks. The CV% were calculated separately for minimum and maximum signals using (Standard deviation/average) *100. Assay parameters such as signal-to-noise (S/N), (S/B) signal-to-background, screening window coefficient (Z') were calculated as described previously (23, 24).

iii) small molecule library screening Each plate had buffer blank, control reaction (minimum signal, with rPtxS1-wt) and maximum signal (NAD⁺ and rGai). Both maximum and minimum signals contain 0.1% DMSO. To correct for inherent fluorescence of compounds separate controls with NAD⁺, Gai and compounds were prepared. Compounds were tested at a concentration of 10 μ M. Compounds displaying inhibition more than 50% were considered as hits. Compound libraries for chemical screening were obtained from NCI repository.

iv) IC₅₀ measurements Assay incubation time was adjusted such that the substrate conversion did not exceed 30% in order to minimize the effect of reduction in substrate concentration while maintaining a robust signal. Compounds were tested from a concentration range of (100-0.01 μ M) in half-log dilution series. Each plate had buffer blank, positive control where PtxS1-wt is added which corresponds to 100% activity and negative control (without enzyme) where the activity was 0%. Control values were included as two half-log units below and above the inhibitor concentration series for reactions with 0% and 100% activity. IC₅₀ values were obtained by fitting data to log (inhibitor) vs response - variable slope using GraphPad (GraphPad software,

Inc.) Chemical structures were drawn using MarvinSketch 5.11.3 (chemAxon) or ChemDraw 18.0 (Perkin-Elmer).

Structure preparation and molecular docking – The 2.7 Å resolution crystal structure of pertussis toxin was accessed from the Protein Data Bank (PDB) (PDB_1BCP (15)). Herein, we considered only the catalytic PtxS1 subunit (1BCP, chain A). Residues 222-269 of PtxS1 were also removed from the coordinate file (see Fig. 1 and 2). The truncated structure was then prepared for docking using the protein preparation wizard (40) in Maestro (Schrödinger Release 2019-1: Maestro, Schrödinger, LLC, New York, NY, 2019). Hydrogen atoms were added, protonation states of ionizable groups were determined and the structure was energy minimized. A grid outlining the binding pocket was specified based on the superimposition of the PtxS1 structure with the S1 subunit of the pertussis-like toxin structure from *E. coli* with bound NAD⁺ (PDB_4Z9D; (22)). The two toxins are 30% identical in primary amino acid sequence. The ligands NSC 228155 (7-nitro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-2,1,3-benzoxadiazole) and NSC 29193 (purine-2,8-dithiol) were prepared for docking using the LigPrep program in Maestro (Schrödinger Release 2019-1: LigPrep, Schrödinger, LLC, New York, NY, 2019). Possible ionization states of the ligands at pH 7.0 ± 2.0 were determined and, in the case of NSC 29193, four tautomeric states were also produced. The ligands were docked to the pertussis S1 structure using the glide XP and SP methods (41), keeping the protein structure rigid but allowing ligand flexibility, producing up to 20 poses for each ligand and tautomer. Since the resulting XP docking poses exhibited few interactions, the SP docking results were pursued further. The poses were ranked according to the glide docking score and free energy of binding calculations made with

the Prime MM-GBSA module (Schrödinger Release 2019-1: Prime, Schrödinger, LLC, New York, NY, 2019).

Molecular dynamics simulation – Molecular dynamics simulation (MDS) of the selected binding poses of NSC 228155 and NSC 29193 bound to the S1 structure was used to study the dynamics of the protein-ligand complexes using the Desmond program (42) in Maestro. The complexes were solvated using a TIP3P water model (43) in an octahedral box, with a 10 Å distance between solute surface atoms and an edge of the box. The systems were neutralized by adding Na⁺ counterions. Additional Na⁺/Cl⁻ ions were added to bring the systems to a 150 mM salt concentration. The simulations were carried out using the OPLS3e force field (44) at constant temperature (300 K) and constant pressure (1 atm), which were respectively regulated using the Nose-Hoover chain thermostat (45) and Martyna-Tobias-Klein barostat (46). Short-range and long-range interactions were computed with a 9 Å distance cutoff. The RESPA integrator (47) was employed with a 6.0 fs time step for long-range non-bonded interactions and a 2.0 fs time step for bonded and short range non-bonded interactions. The systems were relaxed with the default equilibration protocol in Desmond, followed by a 100 ns production simulation. Energies were saved every 1.2 ps, whereas coordinates were recorded every 100 ps. The resulting trajectories were analyzed in terms of ligand stability (as root mean squared deviation, RMSD) and lifetime of protein-ligand interactions using the Simulation Interactions Diagram application in Desmond.

***In vivo* ADP-ribosylation assay** – HEK293T cells grown in DMEM + 10% FBS were seeded in 3 mL volumes in 6-well plates (500 000 cells/well) in the late afternoon. The next morning fresh media containing NSC 228155 at concentrations of 0.1, 1 and 5 µM was exchanged to the cells

(0.05% DMSO in all reactions, including control reactions). Cells were incubated for 30 minutes at 37°C under normal cell culturing conditions, after which 10 ng/mL of pertussis AB₅ holotoxin (List Biological Laboratories Inc., 179A) was added to the cells and incubation was continued for 2 h. Cells were then transferred on ice and washed twice with 1 × PBS and collected into 70 µL of lysis buffer [50 mM Tris-HCl (pH 7.5), 400 mM NaCl, 0.1% sodium deoxycholate, 1% NP-40, 75 µM tannic acid (PARG inhibitor), 40 µM PJ34 (PARP inhibitor) supplemented with Pierce Protease and Phosphatase Inhibitor Mini Tablets (40 µL/mL of stock solution – one tablet / 2 mL H₂O, Thermo Scientific, 88668). Samples were kept on ice for 30 minutes and centrifuged for 15 minutes, 4°C, 16100 × g. Protein concentration was measured from the supernatants with Bradford protein assay. The samples were scaled for protein content to allow loading of 30 µg of total protein per lane in the SDS-PAGE. Laemmli loading dye was added to 1 × and the samples were boiled for 10 minutes at 95°C. The samples were run on SDS-PAGE and transferred to nitrocellulose membranes, followed by blocking with 4% (w/v) BSA in TBST. Membranes were probed in TBST containing 2% (w/v) BSA for mono-ADP-ribose with custom in-house rabbit polyclonal anti-mono-ADP-ribose (1:1000) (Hottiger-laboratory), for GAPDH with mouse monoclonal anti-GAPDH (1:1000) (Abcam, ab9484), for Gai with mouse monoclonal anti-Gai (1:500) (Santa Cruz Biotechnology, sc-136478), for poly-ADP-ribose with rabbit polyclonal anti-PAR (1:1000) (Enzo Life Sciences, ALX-210-890A) and for PARP1 with mouse monoclonal anti-PARP1 (1:300) (Santa Cruz Biotechnology, sc-8007). Membranes were washed thrice with TBST containing 2% (w/v) BSA for ten minutes each time. Membranes were incubated in TBST containing 2% (w/v) BSA with mouse IgG kappa binding protein conjugated to horseradish peroxidase (1:5000) (sc-516102, Santa Cruz Biotechnology) or goat anti-rabbit IgG conjugated to horseradish peroxidase (1:5000) (sc-2004, Santa Cruz Biotechnology) for 3 h at 4°C on a rotary

and washed thrice with TBST for ten minutes each time. Membranes were subsequently developed with WesternBright ECL (Advansta) and imaged on ImageQuant LAS 4000 (GE Healthcare).

MTT cell viability assay – HEK293T cells grown in DMEM + 10% FBS were seeded in 100 μ L volumes in 96-well plates (20 000 cells/well) in the late afternoon. The next morning fresh media containing varying concentrations (0, 0.1, 0.5, 1, 2.5, 5, 10, 20, 40, 60 μ M) of NSC 228155 was added in triplicate. In all the wells final concentration of DMSO was 0.6%. Cells were incubated for 2.5 h at 37°C under normal cell culturing conditions. Cell viability was investigated using the CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT) (Promega, G4002) according to the manufacturer's instructions. Incubation time with the MTT dye solution was 1 h at 37°C under normal cell culturing conditions. NSC 228155 cytotoxicity IC₅₀ value was calculated using GraphPad (GraphPad software, Inc.) Data are displayed as means and the standard error of the mean. Data were normalized to cells treated with 0.6% DMSO (negative controls, 100% viability) and cells killed with 200 μ M H₂O₂ (positive control, 0% viability) and expressed as percentage of these controls. Normalized response is compared to common log of the inhibitor concentration (μ M) and the IC₅₀ calculated using a variable slope. Statistical analyses were conducted using two-tailed Student's t-test two sample equal variance (homoscedastic).

ACKNOWLEDGMENTS

The research in the laboratory of A.T.P. is financially supported by Academy of Finland (grant no. 295296), Sigrid Jusélius Foundation, Turku Doctoral Programme of Molecular Medicine (TuDMM) (to M.M.) and University of Turku, Turku, Finland. This work was funded in the L.L. laboratory by Academy of Finland (grant no. 287063, 294085 and 319299). The use of the facilities of the Biocenter Oulu for DNA sequencing, Proteomics and Protein Analysis and Protein Crystallography, a member of Biocenter Finland and Instruct-FI, are gratefully acknowledged. The laboratory of M.S.J. is supported by Sigrid Jusélius Foundation, Joe, Pentti and Tor Memorial Fund, and Doctoral Network of Informational and Structural Biology (to M.T., Åbo Akademi Graduate School); computational infrastructure and core faculty support from Biocenter Finland (bioinformatics, structural biology and drug discovery and chemical biology nodes), CSC IT Center for Science; Academy of Finland FIRI infrastructure funding (grant no. 320005); screening core faculty of Biocity Turku, and Drug Discovery and Diagnostics strategic funding to Åbo Akademi University. We thank Dr. Jukka Lehtonen for his scientific IT support. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The authors declare that they have no conflicts of interest.

REFERENCES

1. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. 2016. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 29:449-86.
2. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. 2017. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis 17:974-980.
3. Skoff TH, Baumbach J, Cieslak PR. 2015. Tracking pertussis and evaluating control measures through enhanced pertussis surveillance, Emerging Infections Program, United States. Emerg Infect Dis 21:1568-73.
4. Thierry-Carstensen B, Dalby T, Stevner MA, Robbins JB, Schneerson R, Trollfors B. 2013. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults - a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine 31:5178-91.
5. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. 2009. First report and detailed characterization of *B. pertussis* isolates not expressing Pertussis Toxin or Pertactin. Vaccine 27:6034-41.
6. Carbonetti NH. 2015. Contribution of pertussis toxin to the pathogenesis of pertussis disease. Pathog Dis 73:ftv073.
7. Melvin JA, Scheller EV, Miller JF, Cotter PA. 2014. *Bordetella pertussis* pathogenesis: current and future challenges. Nat Rev Microbiol 12:274-88.
8. Morse SI, Morse JH. 1976. Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of *Bordetella pertussis*. J Exp Med 143:1483-502.
9. Hall E, Parton R, Wardlaw AC. 1994. Cough production, leucocytosis and serology of rats infected intrabronchially with *Bordetella pertussis*. J Med Microbiol 40:205-13.

10. Parton R, Hall E, Wardlaw AC. 1994. Responses to *Bordetella pertussis* mutant strains and to vaccination in the coughing rat model of pertussis. J Med Microbiol 40:307-12.
11. Scanlon KM, Snyder YG, Skerry C, Carbonetti NH. 2017. Fatal pertussis in the neonatal mouse model is associated with pertussis toxin-mediated pathology beyond the airways. Infect Immun 85.
12. Stein PE, Boodhoo A, Armstrong GD, Cockle SA, Klein MH, Read RJ. 1994. The crystal structure of pertussis toxin. Structure 2:45-57.
13. Stein PE, Boodhoo A, Armstrong GD, Heerze LD, Cockle SA, Klein MH, Read RJ. 1994. Structure of a pertussis toxin-sugar complex as a model for receptor binding. Nat Struct Biol 1:591-6.
14. Weiss AA, Johnson FD, Burns DL. 1993. Molecular characterization of an operon required for pertussis toxin secretion. Proc Natl Acad Sci U S A 90:2970-4.
15. Hazes B, Boodhoo A, Cockle SA, Read RJ. 1996. Crystal structure of the pertussis toxin-ATP complex: a molecular sensor. J Mol Biol 258:661-71.
16. Simon NC, Aktories K, Barbieri JT. 2014. Novel bacterial ADP-ribosylating toxins: structure and function. Nat Rev Microbiol 12:599-611.
17. Katada T, Ui M. 1982. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A 79:3129-33.
18. West RE, Moss J, Vaughan M, Liu T, Liu TY. 1985. Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site. J Biol Chem 260:14428-30.

19. Graf R, Codina J, Birnbaumer L. 1992. Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding proteins. *Mol Pharmacol* 42:760-4.
20. Weis WI, Kobilka BK. 2018. The molecular basis of G protein-coupled receptor activation. *Annu Rev Biochem* 87:897-919.
21. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M. 1989. Mutants of pertussis toxin suitable for vaccine development. *Science* 246:497-500.
22. Littler DR, Ang SY, Moriel DG, Kocan M, Kleifeld O, Johnson MD, Tran MT, Paton AW, Paton JC, Summers RJ, Schembri MA, Rossjohn J, Beddoe T. 2017. Structure-function analyses of a pertussis-like toxin from pathogenic *Escherichia coli* reveal a distinct mechanism of inhibition of trimeric G-proteins. *J Biol Chem* 292:15143-15158.
23. Putt KS, Hergenrother PJ. 2004. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. *Anal Biochem* 326:78-86.
24. Venkannagari H, Fallarero A, Feijs KL, Lüscher B, Lehtiö L. 2013. Activity-based assay for human mono-ADP-ribosyltransferases ARTD7/PARP15 and ARTD10/PARP10 aimed at screening and profiling inhibitors. *Eur J Pharm Sci* 49:148-56.
25. Locht C, Keith JM. 1986. Pertussis toxin gene: nucleotide sequence and genetic organization. *Science* 232:1258-64.
26. Nicosia A, Perugini M, Franzini C, Casagli MC, Borri MG, Antoni G, Almoni M, Neri P, Ratti G, Rappuoli R. 1986. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. *Proc Natl Acad Sci U S A* 83:4631-5.

27. Moss J, Stanley SJ, Burns DL, Hsia JA, Yost DA, Myers GA, Hewlett EL. 1983. Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of *Bordetella pertussis* toxin (islet-activating protein). J Biol Chem 258:11879-82.
28. Finck-Barbançon V, Barbieri JT. 1996. Preferential processing of the S1 subunit of pertussis toxin that is bound to eukaryotic cells. Mol Microbiol 22:87-95.
29. Sakanyan V, Hulin P, Alves de Sousa R, Silva VA, Hambardzumyan A, Nedellec S, Tomasoni C, Logé C, Pineau C, Roussakis C, Fleury F, Artaud I. 2016. Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1. Sci Rep 6:21088.
30. Lüscher B, Bütepage M, Eckeï L, Krieg S, Verheugd P, Shilton BH. 2018. ADP-ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease. Chem Rev 118:1092-1136.
31. Winter K, Zipprich J, Harriman K, Murray EL, Gornbein J, Hammer SJ, Yeganeh N, Adachi K, Cherry JD. 2015. Risk factors associated with infant deaths from pertussis: a case-control study. Clin Infect Dis 61:1099-106.
32. Guillot S, Descours G, Gillet Y, Etienne J, Floret D, Guiso N. 2012. Macrolide-resistant *Bordetella pertussis* infection in newborn girl, France. Emerg Infect Dis 18:966-8.
33. Wang Z, Li Y, Hou T, Liu X, Liu Y, Yu T, Chen Z, Gao Y, Li H, He Q. 2013. Appearance of macrolide-resistant *Bordetella pertussis* strains in China. Antimicrob Agents Chemother 57:5193-4.
34. Acquaye-Seedah E, Huang Y, Sutherland JN, DiVenere AM, Maynard JA. 2018. Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking. Cell Microbiol 20:e12948.

35. Nguyen AW, Wagner EK, Laber JR, Goodfield LL, Smallridge WE, Harvill ET, Papin JF, Wolf RF, Padlan EA, Bristol A, Kaleko M, Maynard JA. 2015. A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. *Sci Transl Med* 7:316ra195.
36. Turgeon Z, Jørgensen R, Visschedyk D, Edwards PR, Legree S, McGregor C, Fieldhouse RJ, Mangroo D, Schapira M, Merrill AR. 2011. Newly discovered and characterized antivirulence compounds inhibit bacterial mono-ADP-ribosyltransferase toxins. *Antimicrob Agents Chemother* 55:983-91.
37. Pinto AF, Ebrahimi M, Saleeb M, Forsberg Å, Elofsson M, Schöler H. 2016. Identification of inhibitors of *Pseudomonas aeruginosa* Exotoxin-S ADP-ribosyltransferase activity. *J Biomol Screen* 21:590-5.
38. Loch C, Cieplak W, Marchitto KS, Sato H, Keith JM. 1987. Activities of complete and truncated forms of pertussis toxin subunits S1 and S2 synthesized by *Escherichia coli*. *Infect Immun* 55:2546-53.
39. Pulliainen AT, Pielles K, Brand CS, Hauert B, Böhm A, Quebatte M, Wepf A, Gstaiger M, Aebersold R, Dessauer CW, Dehio C. 2012. Bacterial effector binds host cell adenylyl cyclase to potentiate Gas-dependent cAMP production. *Proc Natl Acad Sci U S A* 109:9581-6.
40. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. 2013. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des* 27:221-34.

41. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J Med Chem* 47:1739-49.
42. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Kolossvary I, Moraes MA, Sacerdoti FD, Salmon JoK, Shan Y, Shaw DE. 2006. Scalable algorithms for molecular dynamics simulations on commodity clusters. *Proceedings of the ACM/IEEE Conference on Supercomputing (SC06)*, Tampa, Florida, 2006, November 11-17
43. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein M. 1983. Comparison of simple potential functions for simulating liquid water. *J Chem Phys* 79: 926–935.
44. Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, Kaus JW, Cerutti DS, Krilov G, Jorgensen WL, Abel R, Friesner RA. 2016. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. *J Chem Theory Comput* 12:281-96.
45. Martyna GJ, Klein ML, Tuckerman M. 1992. Nose-Hoover chains - the canonical ensemble via continuous dynamics. *J. Chem. Phys.* 97: 2635-2643.
46. Martyna GJ, Tobias DJ, Klein ML. 1994. Constant-pressure molecular dynamics algorithms. *J Chem Phys* 101: 4177-4189.
47. Tuckerman M, Berne BJ, Martyna GJ. 1992. Reversible multiple time scale molecular dynamics. *J Chem Phys* 97:1990-2001.

FIGURE LEGENDS

Figure 1. PtxS1 of pertussis toxin. **A)** Surface representation of the crystal structure of PtxS1 (PDB_1BCP, chain A). The truncated C-terminal fragment and the truncation-uncovered ART active site are shown in yellow and dark grey, respectively. **B)** Possible binding mode of NAD^+ to PtxS1 derived by superimposing the PtxS1 crystal structure (PDB_1BCP, chain A) to the crystal structure of active site mutant of pertussis-like toxin from *E. coli* with bound NAD^+ (PDB_4Z9D). Color-coding of atoms in NAD^+ : yellow, carbon; blue, nitrogen; red, oxygen; magenta, phosphorus.

Figure 2. Catalytic activity of rPtxS1. **A)** Construct design. rPtxS1 lacks the N-terminal secretion signal (S) as well as part of the C-terminus (C-term). N-terminus of the mature PtxS1 starting with Asp35 is classically numbered as the first amino acid of PtxS1. **B)** PageBlue-stained SDS-PAGE gel of SEC-purified rPtxS1. **C)** Representative SEC-MALS result of SEC-purified rPtxS1. **D)** Representative DSF result of SEC-purified rPtxS1. **E)** *In vitro* ADP-ribosylation assay (enzyme-excess condition) for rPtxS1 with NAD^+ -biotin and HEK293T membrane fraction with endogenous level of G α_i . Protein-conjugated ADP-ribose-biotin is detected with streptavidin-HRP. **F)** *In vitro* ADP-ribosylation assay (enzyme-excess condition) for rPtxS1 with NAD^+ and recombinant N-terminally HIS-tagged G α_i . Protein-conjugated ADP-ribose is detected with a rabbit polyclonal antibody specific for mono-ADP-ribose (MAR). Same samples were analyzed in three (Fig. 2E) and two (Fig. 2F) parallel membranes, respectively.

Figure 3. Multiwell fluorometric NAD⁺ quantitation assay. Decrease in fluorescence over time is a measure of NAD⁺-consuming enzymatic activity. **A)** rPtxS1 and rPtxS1-mutant were incubated for 40 min in the presence or for 60 min in the absence of rGai substrate. **B)** Time and concentration dependency of NAD⁺-consuming enzymatic activity of rPtxS1 in the presence of rGai substrate. **C)** Effect of DMSO on NAD⁺-consuming enzymatic activity of rPtxS1 in the presence of rGai substrate. Statistics based on two-tailed Student's t-test two sample equal variance (homoscedastic).

Figure 4. Evaluation of primary compound hits from rPtxS1 inhibitor screen. **A)** *In vitro* ADP-ribosylation assay (substrate-excess condition) for N-terminally HIS-tagged rPtxS1 with NAD⁺-biotin and N-terminally HIS-tagged rGai. Protein-conjugated biotin-ADP-ribose was detected with streptavidin-HRP. The reactions contained 200-fold molar excess of inhibitors over rPtxS1. Compounds marked with asterisks affect rPtxS1 and/or rGai protein integrity, and were therefore excluded from further studies. Same samples were analyzed in two parallel membranes. **B)** IC₅₀-curves of the hit compounds selected based on Fig. 3A data. **C)** Chemical structures of NAD⁺ and hit compounds NSC 228155 and NSC 29193 with < 10 μM IC₅₀-values.

Figure 5. Prediction of binding poses of NSC 228155 and NSC 29193 to PtxS1. Selected binding poses 1 **A)** and 2 **B)** of NSC 228155 and binding poses 1 **C)** and 2 **D)** of NSC 29193 to PtxS1 (PDB_1BCP, chain A), and residues involved in ligand interactions. Binding mode of NAD⁺ to PtxS1 in the corresponding area of the NAD⁺-binding pocket is shown in each panel on the right (see also Fig. 1). Color-coding of atoms in NAD⁺: yellow, carbon; blue, nitrogen; red, oxygen; magenta, phosphorus. Hydrogen bond interactions are shown in dotted lines.

Figure 6. Evaluation of NSC 228155 in a living human cell-based assay. NSC 228155 inhibits pertussis holotoxin-mediated mono-ADP-ribosylation of Gαi in living HEK293T cells. **A)** Effect of pertussis holotoxin concentration on mono-ADP-ribosylation of Gαi in 2 h incubation with living HEK293T cells. **B)** Effect of NSC 228155 concentration on mono-ADP-ribosylation of Gαi in living HEK293T cells. Inhibitors were added 30 min before starting the 2 h holotoxin incubation. Protein-conjugated ADP-ribose is detected with a rabbit polyclonal antibody specific for mono-ADP-ribose (MAR). [#]Western blot of a parallel membrane with the same Fig. 6B samples, otherwise Fig. 6A and Fig. 6B blots probed, stripped and re-probed in the order of 1) anti-MAR, 2) anti-GAPDH and 3) anti-Gαi.




Figure 1. PtxS1 of pertussis toxin. A) Surface representation of the crystal structure of PtxS1 (PDB_1BCP, chain A). The truncated C-terminal fragment and the truncation-uncovered ART active site are shown in yellow and dark grey, respectively. **B)** Possible binding mode of NAD⁺ to PtxS1 derived by superimposing the PtxS1 crystal structure (PDB_1BCP, chain A) to the crystal structure of active site mutant of pertussis-like toxin from *E. coli* with bound NAD⁺ (PDB_4Z9D). Color-coding of atoms in NAD⁺: yellow, carbon; blue, nitrogen; red, oxygen; magenta, phosphorus.




Figure 2. Catalytic activity of rPtxS1. **A)** Construct design. rPtxS1 lacks the N-terminal secretion signal (S) as well as part of the C-terminus (C-term). N-terminus of the mature PtxS1 starting with Asp35 is classically numbered as the first amino acid of PtxS1. **B)** PageBlue-stained SDS-PAGE gel of SEC-purified rPtxS1. **C)** Representative SEC-MALS result of SEC-purified rPtxS1. **D)** Representative DSF result of SEC-purified rPtxS1. **E)** *In vitro* ADP-ribosylation assay (enzyme-excess condition) for rPtxS1 with NAD⁺-biotin and HEK293T membrane fraction with endogenous level of Gai. Protein-conjugated ADP-ribose-biotin is detected with streptavidin-HRP. **F)** *In vitro* ADP-ribosylation assay (enzyme-excess condition) for rPtxS1 with NAD⁺ and recombinant N-terminally HIS-tagged Gai. Protein-conjugated ADP-ribose is detected with a custom in-house rabbit polyclonal antibody specific for mono-ADP-ribose. Same samples were analyzed in three (Fig. 2E) and two (Fig. 2F) parallel membranes, respectively.





Figure 3. Multiwell fluorometric NAD⁺ quantitation assay. Decrease in fluorescence over time is a measure of NAD⁺-consuming enzymatic activity. **A)** rPtxS1 and rPtxS1-mutant were incubated for 40 min in the presence or for 60 min in the absence of rGai substrate. **B)** Time and concentration dependency of NAD⁺-consuming enzymatic activity of rPtxS1 in the presence of rGai substrate. **C)** Effect of DMSO on NAD⁺-consuming enzymatic activity of rPtxS1 in the presence of rGai substrate. Statistics based on two-tailed Student's t-test two sample equal variance (homoscedastic).



C

NSC 29193

NSC 228155

NAD⁺

Figure 4. Evaluation of primary compound hits from rPtXS1 inhibitor screen.

A *In vitro* ADP-ribosylation assay (substrate-excess condition) for N-terminally HIS-tagged rPtXS1 with NAD⁺-biotin and N-terminally HIS-tagged rGai. Protein-conjugated biotin-ADP-ribose was detected with streptavidin-HRP. The reactions contained 200-fold molar excess of inhibitors over rPtXS1. Compounds marked with an asterisk affect rPtXS1 and/or rGai protein integrity, and were therefore excluded from further studies. Same samples were analyzed in two parallel membranes. **B** IC_{50} -curves of the hit compounds selected based on Fig. 3A data. **C** Chemical structures of NAD⁺ and hit compounds NSC 228155 and NSC 29193 with < 10 μM IC_{50} -values.




Figure 5. Prediction of binding poses of NSC 228155 and NSC 29193 to PtxS1. Selected binding poses 1 **A**) and 2 **B**) of NSC 228155 and binding poses 1 **C**) and 2 **D**) of NSC 29193 to PtxS1 (PDB_1BCP, chain A), and residues involved in ligand interactions. Binding mode of NAD⁺ to PtxS1 in the corresponding area of the NAD⁺-binding pocket is shown in each panel on the right (see also Fig. 1). Color-coding of atoms in NAD⁺: yellow, carbon; blue, nitrogen; red, oxygen; magenta, phosphorus. Hydrogen bond interactions are shown in dotted lines.




Figure 6. Evaluation of NSC 228155 in a living human cell-based assay. NSC 228155 inhibits pertussis holotoxin-mediated mono-ADP-ribosylation of Gai in living HEK293T cells. **A)** Effect of pertussis holotoxin concentration on mono-ADP-ribosylation of Gai in 2 h incubation with living HEK293T cells. **B)** Effect of NSC 228155 concentration on mono-ADP-ribosylation of Gai in living HEK293T cells. Inhibitors were added 30 min before starting the 2 h holotoxin incubation. Protein-conjugated ADP-ribose is detected with a custom in-house rabbit polyclonal antibody specific for mono-ADP-ribose (MAR). [#]Western blot of a parallel membrane with the same Fig. 6B samples, otherwise Fig. 6A and Fig. 6B blots probed, stripped and re-probed in the order of 1) anti-MAR, 2) anti-GAPDH and 3) anti-Gai.